Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways

doi:10.3748/wjg.v23.i24.4354

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12151)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-11) series, Tables (1-1) series.

Item

Count

PDF

692

WORD

320

HTML

5724

Figures (1-11)

349

Tables (1-1)

297

Sum=7382

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

784

Download

1205

Sum=1989

Publishing Process of This Article

Item

Count

Browse

1092

Download

1688

Sum=2780

Jun 28, 2017 (publication date) through Jan 31, 2025

Times Cited of This Article

Times Cited (72)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jun 28, 2017; 23(24): 4354-4368
Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4354

Full Size Figure Download Figure

Figure 4 Naringenin prevents oxidative stress in CCl₄-treated rats. Lipid peroxidation (A), reduced glutathione (GSH) determinations in liver (B) and blood (C) and GPx activity (D) from control rats, carbon tetrachloride (CCl₄)-treated rats, CCl₄ plus naringenin rats (CCl₄ + NAR), and rats administered with NAR alone (NAR). Each bar represents the mean value of experiments performed in duplicate assay ± SE (n = 8). ^aP < 0.05 vs control group; ^bP < 0.05 vs CCl₄ group.

Citation: Hernández-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltrán RE, Arauz J, Shibayama M, Favari L, Tsutsumi V, Segovia J, Muriel P. Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways. World J Gastroenterol 2017; 23(24): 4354-4368
URL: https://www.wjgnet.com/1007-9327/full/v23/i24/4354.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i24.4354